EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study

Fevzi Necati Avsar iD, Nihat Kılıcaslan, Tuncay Sahutoglu iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0357671 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS One, 2026. Verfasst von Fevzi Necati Avsar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Sanliurfa Mehmet Akif Inan Training and Research Hospital, University of Health Sciences, Türkiye. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Interleukin 1 Receptor Antagonist Protein, Hospital Mortality, COVID-19 Drug Treatment. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interleukin-1 and interleukin-6 blockade have been widely used in severe COVID-19, but comparative real-world evidence regarding anakinra and tocilizumab in critically ill patients remains limited. We evaluated the associations of first initiation of anakinra or tocilizumab with 28-day and overall in-hospital mortality.

Methods

This single-center retrospective ICU cohort included adults with severe COVID-19. During hospital days 2–10, daily actions were classified as anakinra initiation, tocilizumab initiation, or control/defer. Calibrated overlap-weighted modified-Poisson models estimated associations with 28-day and overall in-hospital mortality; ferritin-adjusted sensitivity analyses were performed.

Results

Of 306 patients, 241 patients contributed 1,297 eligible person-days. Calibration met the prespecified balance criterion for the included covariates, although effective support for tocilizumab initiation remained limited. For 28-day in-hospital mortality, adjusted RRs versus control/defer were 0.99 (95% CI, 0.80–1.22) for anakinra and 0.99 (95% CI, 0.71–1.37) for tocilizumab. No clear associations were identified in the head-to-head comparison or for overall in-hospital mortality; ferritin-adjusted estimates were similar.

Conclusions

In this retrospective ICU cohort, neither anakinra nor tocilizumab initiation showed a clear association with 28-day or overall in-hospital mortality. Estimates were imprecise, particularly for tocilizumab, and remain susceptible to residual confounding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedInterleukin 1 Receptor Antagonist ProteinHospital MortalityCOVID-19 Drug TreatmentHumansFemaleRetrospective StudiesMaleCOVID-19AgedMiddle AgedSARS-CoV-2Intensive Care Units

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedInterleukin 1 Receptor Antagonist Protein

Autor:innen und Institutionen

  • Department of Internal Medicine, Sanliurfa Mehmet Akif Inan Training and Research Hospital, University of Health Sciences, Türkiye.
  • Department of Radiology, Sanliurfa Mehmet Akif Inan Training and Research Hospital, University of Health Sciences, Türkiye.
  • Division of Nephrology, Department of Internal Medicine, Sanliurfa Mehmet Akif Inan Training and Research Hospital, University of Health Sciences, Türkiye.

ORCID-Profile: Fevzi Necati Avsar, Tuncay Sahutoglu

Zitieren

APA

Avsar, F. N., Kılıcaslan, N., & Sahutoglu, T. (2026). Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0357671

Vancouver

Avsar FN, Kılıcaslan N, Sahutoglu T. Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study. PLOS One. 2026. doi:10.1371/journal.pone.0357671

BibTeX
@article{Avsar2026,
  author = {Avsar, Fevzi Necati and Kılıcaslan, Nihat and Sahutoglu, Tuncay},
  title = {Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0357671}
}
Kostenlos starten →